Premium
In vivo effects of mesalazine or E. coli Nissle 1917 on microsatellite instability in ulcerative colitis
Author(s) -
GOEL A.,
MITTAL A.,
EVSTATIEV R.,
NEMETH M.,
KRUIS W.,
STOLTE M.,
BOLAND C. R.,
GASCHE C.
Publication year - 2009
Publication title -
alimentary pharmacology and therapeutics
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 3.308
H-Index - 177
eISSN - 1365-2036
pISSN - 0269-2813
DOI - 10.1111/j.1365-2036.2009.04076.x
Subject(s) - microsatellite instability , mesalazine , ulcerative colitis , medicine , colorectal cancer , gastroenterology , colitis , cancer , biopsy , rectum , microsatellite , in vivo , pathology , gene , biology , genetics , disease , allele
Summary Background Microsatellite instability (MSI) occurs in chronically inflamed colorectal tissue and may evolve to colitis‐associated cancer. In vitro data suggest that mesalazine (5‐ASA) improves MSI. Aim To analyse the changes in MSI in 156 distal colonic biopsies of 39 patients with ulcerative colitis that had been treated within a randomized, double‐blind trial comparing 5‐ASA with E. coli Nissle (EcN). Methods Two biopsies had been collected before and after 1 year of treatment. MSI testing was performed using a panel of eight markers, including 3 dinucleotide and 5 mononucleotide repeats. Results No MSI was observed with any of the mono‐repeats, and among dinucleotide repeats, only D5S346 (maps to APC ) and D17S250 (p53) were consistently informative. Overall, 31/156 (20%) biopsies displayed MSI. After 1 year, 3/11 patients displayed MSI improvement [change to microsatellite stability (MSS); 1 on 5‐ASA, 2 on EcN] at D5S346 and 4/11 showed MSI worsening (change from MSS to MSI; all 5‐ASA). For D17S250, the corresponding data were for 3/9 patients (2 on 5‐ASA, 1 on EcN) and 2/9 (both on 5‐ASA), respectively. Conclusions In the set of biopsies taken from patients treated with 1.5 g 5‐ASA for 1 year, there was no improvement in the prevalence of MSI in the distal colon.